Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by G1945Von Dec 31, 2022 5:04pm
88 Views
Post# 35198679

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Midatech at $1.0475

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Midatech at $1.0475
KayakerBC wrote: So the higher the Midatech stock price goes up from here to the closing of the arrangement the better.

I doubt it will go up too much (unless BTI does too).  As the closing gets closer I would expect there to be less arbitrage opportunity.



"My understanding:  If, for example, you have 10,000 BTI shares, upon closing, that gets converted to 9556 "Ordinary Shares" in the form of American Depositary Shares (ADS), rounded down to the nearest whole ADS.  Each ADS represents 25 Ordinary Shares.  So that 9556 Ordinary Shares becomes 382.24 (round down) to 382 ADS in Biodexa Therapeutics."

KBC (final question) Is this conversation formula fixed between now and the closing of the agreement? Or will there be a recalibration at some point? 

G1945V

<< Previous
Bullboard Posts
Next >>